Stephen H. Gillespie
Stephen H. Gillespie has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Timothy Daniel McHugh
Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, UK
4 shared publications Bambos M. Charalambous
Centre for Medical Microbiology, University College London, Royal Free Campus, Rowland Hill St., London NW3 2PF,1 Specialist and Reference Microbiology Division, Health Protection Agency, 67, Colindale Avenue, London NW9 5HT, United Kingdom2
3 shared publicationsAnne Dickens
2 shared publicationsDean Everett
Department of Medical Microbiology, University College London, Royal Free Campus, London NW3 2PF,1 London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom,2 Huruma Hospital, Huruma,3 Clinical Laboratory, Kilimanjaro Christian Medical College, Moshi, Tanzania,4 Pfizer Inc., New York, New York 10017-57555
2 shared publicationsLeroy L. Voelker
2 shared publicationsSarah L. Batt
Centre for Medical Microbiology, University College London, Royal Free Campus, Rowland Hill St., London NW3 2PF, United Kingdom.
2 shared publications
Latest Publications
- Open Access
- 1 June 2005
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (6) , 2656-2661
Novel PCR-Restriction Fragment Length Polymorphism Method for Determining Serotypes or Serogroups of Streptococcus pneumoniae Isolates
Serotyping Streptococcus pneumoniae is a technique generally confined to reference laboratories, as purchasing pneumococcal antisera is a huge investment. Many attempts have been made to modify serological agglutination techniques to make them more accessible, and more recently developments in serotyping have focused on molecular techniques. This paper describes a PCR assay which amplifies the entire capsulation locus between dexB and aliA . Amplicons are digested to produce serotype-specific patterns. We have shown, using 81 epidemiologically unrelated strains representing 46 different serotypes, that the patterns correlate with a 90 to 100% similarity range for the same serotype or serogroup. Prospective testing of 73 isolates of unknown serotype confirmed reliable serotype attribution, and serotype profiles are reproducible on repeated testing. Once our database contains all 90 serotypes, this technique should be fully portable, cost-effective, and useful in any laboratory with sufficient molecular experience.
- 1 June 2005
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (6) , 2656-2661
Open AccessNovel PCR-Restriction Fragment Length Polymorphism Method for Determining Serotypes or Serogroups of Streptococcus pneumoniae Isolates
Serotyping Streptococcus pneumoniae is a technique generally confined to reference laboratories, as purchasing pneumococcal antisera is a huge investment. Many attempts have been made to modify serological agglutination techniques to make them more accessible, and more recently developments in serotyping have focused on molecular techniques. This paper describes a PCR assay which amplifies the entire capsulation locus between dexB and aliA . Amplicons are digested to produce serotype-specific patterns. We have shown, using 81 epidemiologically unrelated strains representing 46 different serotypes, that the patterns correlate with a 90 to 100% similarity range for the same serotype or serogroup. Prospective testing of 73 isolates of unknown serotype confirmed reliable serotype attribution, and serotype profiles are reproducible on repeated testing. Once our database contains all 90 serotypes, this technique should be fully portable, cost-effective, and useful in any laboratory with sufficient molecular experience.
- Open Access
- 15 November 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (10) , 1431-1432
Studies of Early Bactericidal Activity: New Insights into Isnoniazid Pharmacokinetics
Studies of early bactericidal activity (EBA) have an important place in the experimental investigation of tuberculosis treatment. Although there are several variations in the clinical protocols used, patients with newly diagnosed drug-susceptible tuberculosis are treated with a single drug or combination of drugs for 2–14 days, and the number of viable colony-forming units (CFUs) in sputum samples is measured serially. Although monotherapy is thought to possibly increase the risk of drug resistance emerging during a given trial, there are no examples of this having occurred in the course of an EBA study. The first such study was performed in Nairobi in the late 1970s and investigated all of the components and drug combinations available for use in antituberculosis therapy. It provided evidence of the relative activity of the different antituberculosis drugs and drug combinations available at that time [1, 2]. The data that emerged from this study [1] have been important in underpinning thinking about how different antituberculosis agents contribute to treatment. For example, Jindani's original study [1] demonstrated that isoniazid had the most bactericidal activity of the antituberculosis drugs; this and other data were important in framing the “special populations” hypothesis of antituberculosis treatment [3].
- 15 November 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (10) , 1431-1432
Open AccessStudies of Early Bactericidal Activity: New Insights into Isnoniazid Pharmacokinetics
Studies of early bactericidal activity (EBA) have an important place in the experimental investigation of tuberculosis treatment. Although there are several variations in the clinical protocols used, patients with newly diagnosed drug-susceptible tuberculosis are treated with a single drug or combination of drugs for 2–14 days, and the number of viable colony-forming units (CFUs) in sputum samples is measured serially. Although monotherapy is thought to possibly increase the risk of drug resistance emerging during a given trial, there are no examples of this having occurred in the course of an EBA study. The first such study was performed in Nairobi in the late 1970s and investigated all of the components and drug combinations available for use in antituberculosis therapy. It provided evidence of the relative activity of the different antituberculosis drugs and drug combinations available at that time [1, 2]. The data that emerged from this study [1] have been important in underpinning thinking about how different antituberculosis agents contribute to treatment. For example, Jindani's original study [1] demonstrated that isoniazid had the most bactericidal activity of the antituberculosis drugs; this and other data were important in framing the “special populations” hypothesis of antituberculosis treatment [3].
- 1 August 2004
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 98 (8) , 505-506
Molecular Diagnosis of Infectious Diseases, 2nd edition
- 1 August 2004
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 98 (8) , 505-506
Molecular Diagnosis of Infectious Diseases, 2nd edition
- 1 February 2004
- Published by Elsevier in The Lancet
- Vol. 363 (9410) , 672-673
New tricks from an old dog: streptococcal necrotising soft-tissue infections
- 1 February 2004
- Published by Elsevier in The Lancet
- Vol. 363 (9410) , 672-673
New tricks from an old dog: streptococcal necrotising soft-tissue infections
- 1 January 2004
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 6 (1) , 50-53
Cutaneous larva migrans
International travel and increasingly exotic diets have resulted in an increase in cases of cutaneous larva migrans in industrialized countries. A broader spectrum of clinical presentation and complications of cutaneous larva migrans is recognized by clinicians. A new syndrome, eosinophilic enteritis, has been described in Australia and may be more widespread as new diagnostic tests are used more widely. Other causes of cutaneous migration, such as gnathostomiasis and sparganosis, should be considered, and a recent outbreak of gnathostomiasis in Mexico suggests that clinicians must be alert to these unusual infections arising in patients outside their traditional distribution.
- 1 January 2004
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 6 (1) , 50-53
Cutaneous larva migrans
International travel and increasingly exotic diets have resulted in an increase in cases of cutaneous larva migrans in industrialized countries. A broader spectrum of clinical presentation and complications of cutaneous larva migrans is recognized by clinicians. A new syndrome, eosinophilic enteritis, has been described in Australia and may be more widespread as new diagnostic tests are used more widely. Other causes of cutaneous migration, such as gnathostomiasis and sparganosis, should be considered, and a recent outbreak of gnathostomiasis in Mexico suggests that clinicians must be alert to these unusual infections arising in patients outside their traditional distribution.
- 1 December 2003
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (12) , 5551-6
Quantitative Validation of Media for Transportation and Storage of Streptococcus pneumoniae
The need to design effective Streptococcus pneumoniae vaccines and to monitor resistance means that it is essential to have efficient methods to determine carriage rates. Two liquid media, consisting of skim milk, glycerol, glucose, and tryptone soya broth (STGG) or skim milk, glycerol, and glucose (SGG) alone, were evaluated for their ability to maintain pneumococcal viability. Optimal recovery of S. pneumoniae was achieved when swabs were transferred to STGG medium prior to plating onto blood agar-gentamicin selective plates (22%) compared to 7% when plated out directly ( P < 0.0001 by Fisher's exact test). Both STGG and SGG media are appropriate for the long-term storage of pneumococci and primary swab samples at −70°C, with no decrease in viable count observed following repeated freeze-thaw cycles. Samples could be stored refrigerated for up to 3 days in either STGG or SGG medium with no significant loss of viability. Viability decreased progressively in storage at 20 to 30°C, with greater losses of viability occurring at the higher temperatures. There were no significant differences in viability between isolates in the two media. STGG preserved pneumococci significantly better (about twofold) than SGG medium at 21°C ( P < 0.0001) and 30°C ( P < 0.0001). Samples can be stored for 4 and 2.5 days at 6 to 8°C, 28 and 17 h at 21°C, and 15 and 7 h at 30°C in STGG and SGG media, respectively. For field studies undertaken in resource-limited environments, SGG medium can be prepared by using locally available materials. The quantitative data reported in this study will enable researchers to plan appropriate transport and storage protocols.
- 1 December 2003
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (12) , 5551-6
Quantitative Validation of Media for Transportation and Storage of Streptococcus pneumoniae
The need to design effective Streptococcus pneumoniae vaccines and to monitor resistance means that it is essential to have efficient methods to determine carriage rates. Two liquid media, consisting of skim milk, glycerol, glucose, and tryptone soya broth (STGG) or skim milk, glycerol, and glucose (SGG) alone, were evaluated for their ability to maintain pneumococcal viability. Optimal recovery of S. pneumoniae was achieved when swabs were transferred to STGG medium prior to plating onto blood agar-gentamicin selective plates (22%) compared to 7% when plated out directly ( P < 0.0001 by Fisher's exact test). Both STGG and SGG media are appropriate for the long-term storage of pneumococci and primary swab samples at −70°C, with no decrease in viable count observed following repeated freeze-thaw cycles. Samples could be stored refrigerated for up to 3 days in either STGG or SGG medium with no significant loss of viability. Viability decreased progressively in storage at 20 to 30°C, with greater losses of viability occurring at the higher temperatures. There were no significant differences in viability between isolates in the two media. STGG preserved pneumococci significantly better (about twofold) than SGG medium at 21°C ( P < 0.0001) and 30°C ( P < 0.0001). Samples can be stored for 4 and 2.5 days at 6 to 8°C, 28 and 17 h at 21°C, and 15 and 7 h at 30°C in STGG and SGG media, respectively. For field studies undertaken in resource-limited environments, SGG medium can be prepared by using locally available materials. The quantitative data reported in this study will enable researchers to plan appropriate transport and storage protocols.
- Open Access
- 1 September 2003
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (9) , 2765-2769
Impact of Azithromycin Administration for Trachoma Control on the Carriage of Antibiotic-Resistant Streptococcus pneumoniae
Community distribution of azithromycin has an important role to play in trachoma control. Previous studies have suggested that this may increase the prevalence of macrolide-resistant Streptococcus pneumoniae. S. pneumoniae was isolated from children under 7 years of age in Rombo District, northern Tanzania, before and 2 and 6 months after community-wide administration of azithromycin. Overall carriage rates were 11, 12, and 7%, respectively. Only one macrolide-resistant isolate carrying the mef gene was obtained 6 months after azithromycin administration. This contrasted with cotrimoxazole and penicillin resistance, both of which were common (cotrimoxazole resistance, 42, 43, and 47%, and penicillin resistance, 21, 17, and 16% at baseline, 2 months, and 6 months, respectively). There was a significant association between cotrimoxazole and penicillin resistance ( P < 0.0001, Fisher's exact). These data suggest that in communities where macrolide resistance is rare, azithromycin distribution for trachoma control is unlikely to increase the prevalence of resistant organisms.
- 1 September 2003
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (9) , 2765-2769
Open AccessImpact of Azithromycin Administration for Trachoma Control on the Carriage of Antibiotic-Resistant Streptococcus pneumoniae
Community distribution of azithromycin has an important role to play in trachoma control. Previous studies have suggested that this may increase the prevalence of macrolide-resistant Streptococcus pneumoniae. S. pneumoniae was isolated from children under 7 years of age in Rombo District, northern Tanzania, before and 2 and 6 months after community-wide administration of azithromycin. Overall carriage rates were 11, 12, and 7%, respectively. Only one macrolide-resistant isolate carrying the mef gene was obtained 6 months after azithromycin administration. This contrasted with cotrimoxazole and penicillin resistance, both of which were common (cotrimoxazole resistance, 42, 43, and 47%, and penicillin resistance, 21, 17, and 16% at baseline, 2 months, and 6 months, respectively). There was a significant association between cotrimoxazole and penicillin resistance ( P < 0.0001, Fisher's exact). These data suggest that in communities where macrolide resistance is rare, azithromycin distribution for trachoma control is unlikely to increase the prevalence of resistant organisms.
- Open Access
- 13 August 2003
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 52 (3) , 473-476
A multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugs
A model for evaluating the potency of a new anti-tuberculosis drug or a drug combination, based on a decline in the number of viable tubercle bacilli in patient’s sputum during 5 days mono-therapy has been reported. One popular measure is based on the analysis of the decline in bacterial counts during the first 48 h of therapy and has been called early bactericidal activity (EBA). Such analyses could detect EBA for only a few drugs and were subject to variations in results obtained in different sites. To address these problems we applied a reiterative exponential decay model to evaluate the data on bacterial counts during 5 days of mono-therapy. The validity of this approach was tested using data from three previously published studies. For patients treated with isoniazid 300 mg daily, the values for the time taken to reduce the viable count by 50% (vt50) measured in days were, from a Kenyan study 0.58 days s.e.m. 0.18, from a Tanzanian study 0.41 days s.e.m. 0.04, and from a United States study 0.55 days s.e.m. 0.12. These differences were not statistically significant (P = 0.77 Kruskal–Wallis non-parametric ANOVA). Mean values of vt50 for all of the major anti-tuberculosis agents showed that there was an overlapping spectrum of activity from isoniazid 300 mg (vt50 0.58 days) to para-amino-salicylic acid (vt50 2.9 days) The variation between column means was greater than could be expected by chance (P = 0.0002 Kruskal–Wallis non-parametric ANOVA). From this, we conclude that the reiterative exponential decay model permits comparison between the data obtained in different centres and would allow the activity of a new drug to be compared with that of the currently available agents.
- 13 August 2003
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 52 (3) , 473-476
Open AccessA multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugs
A model for evaluating the potency of a new anti-tuberculosis drug or a drug combination, based on a decline in the number of viable tubercle bacilli in patient’s sputum during 5 days mono-therapy has been reported. One popular measure is based on the analysis of the decline in bacterial counts during the first 48 h of therapy and has been called early bactericidal activity (EBA). Such analyses could detect EBA for only a few drugs and were subject to variations in results obtained in different sites. To address these problems we applied a reiterative exponential decay model to evaluate the data on bacterial counts during 5 days of mono-therapy. The validity of this approach was tested using data from three previously published studies. For patients treated with isoniazid 300 mg daily, the values for the time taken to reduce the viable count by 50% (vt50) measured in days were, from a Kenyan study 0.58 days s.e.m. 0.18, from a Tanzanian study 0.41 days s.e.m. 0.04, and from a United States study 0.55 days s.e.m. 0.12. These differences were not statistically significant (P = 0.77 Kruskal–Wallis non-parametric ANOVA). Mean values of vt50 for all of the major anti-tuberculosis agents showed that there was an overlapping spectrum of activity from isoniazid 300 mg (vt50 0.58 days) to para-amino-salicylic acid (vt50 2.9 days) The variation between column means was greater than could be expected by chance (P = 0.0002 Kruskal–Wallis non-parametric ANOVA). From this, we conclude that the reiterative exponential decay model permits comparison between the data obtained in different centres and would allow the activity of a new drug to be compared with that of the currently available agents.
- 1 August 2003
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 52 (8) , 609-613
Severe acute respiratory syndrome (SARS): breath-taking progress
Reports of a new severe respiratory disease, now defined as severe acute respiratory syndrome (SARS), began to emerge from Guangdong, in southern China, in late 2002. The condition came to international attention through an explosive outbreak in Hong Kong in March 2003. Cases appeared throughout South-East Asia and in Toronto, the spread of SARS being accelerated by international air travel. A global emergency was declared by the World Health Organization, bringing together an international team of epidemiologists, public health physicians and microbiologists to study and contain the disease. This response has enabled the nature of the infectious agent to be identified, its mode of transmission to be established and diagnostic tests to be created rapidly.
- 1 August 2003
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 52 (8) , 609-613
Severe acute respiratory syndrome (SARS): breath-taking progress
Reports of a new severe respiratory disease, now defined as severe acute respiratory syndrome (SARS), began to emerge from Guangdong, in southern China, in late 2002. The condition came to international attention through an explosive outbreak in Hong Kong in March 2003. Cases appeared throughout South-East Asia and in Toronto, the spread of SARS being accelerated by international air travel. A global emergency was declared by the World Health Organization, bringing together an international team of epidemiologists, public health physicians and microbiologists to study and contain the disease. This response has enabled the nature of the infectious agent to be identified, its mode of transmission to be established and diagnostic tests to be created rapidly.